Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.44 |
| ▸ | CNR1 | P21554 | 10/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21506637 | 1.00 | CNR2 (0.44) | CNR2CNR1EGLN1SLC6A12MEN1 | |
| SCHEMBL21481907 | 0.92 | EGLN1 (0.39) | CNR2CNR1EGLN1SLC6A12DGAT1 | |
| SCHEMBL21481825 | 0.90 | CNR2 (0.47) | CNR2CNR1EGLN1MEN1KMT2A | |
| SCHEMBL21506538 | 0.89 | DRD4 (0.43) | CNR2CNR1EGLN1SLC6A12P2RX7 | |
| SCHEMBL21458113 | 0.88 | PTGER4 (0.44) | CNR2CNR1EGLN1SLC6A12MEN1 | |
| SCHEMBL21481845 | 0.88 | PTGER4 (0.44) | CNR2CNR1EGLN1SLC6A12MEN1 | |
| SCHEMBL21481816 | 0.87 | MEN1 (0.44) | CNR2CNR1EGLN1SLC6A12MEN1 | |
| SCHEMBL24991885 | 0.86 | CNR2 (0.42) | CNR2CNR1EGLN1MEN1KMT2A | |
| SCHEMBL21485581 | 0.84 | KDM4E (0.40) | CNR2CNR1EGLN1SLC6A12MEN1 | |
| SCHEMBL21481821 | 0.83 | DRD2 (0.46) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885EGLN1 336/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885EGLN1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.